(-0.03%) 5 477.00 points
(-0.06%) 38 794 points
(0.02%) 19 925 points
(0.29%) $80.56
(1.26%) $2.82
(0.20%) $2 333.70
(-0.24%) $29.32
(-0.18%) $969.20
(0.01%) $0.932
(-0.15%) $10.64
(0.06%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS)...
Stats | |
---|---|
Šios dienos apimtis | 154 685 |
Vidutinė apimtis | 204 058 |
Rinkos kapitalizacija | 92.43M |
EPS | $-0.220 ( Q3 | 2024-02-13 ) |
Kita pelno data | ( $-0.410 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-2.25 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0140 (0.41%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Rotunno Mary L. | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Gin Jerry B | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Fitzpatrick Margaret M | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Curley Joanne | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Cunningham Ann Michelle | Buy | 12 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
99.29 |
Last 94 transactions |
Buy: 11 348 392 | Sell: 716 774 |
Tūris Koreliacija
VistaGen Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
VistaGen Therapeutics Inc Koreliacija - Valiuta/Žaliavos
VistaGen Therapeutics Inc Finansinės ataskaitos
Annual | 2024 |
Pajamos: | $1.06M |
Bruto pelnas: | $1.06M (100.00 %) |
EPS: | $-0.00150 |
FY | 2024 |
Pajamos: | $1.06M |
Bruto pelnas: | $1.06M (100.00 %) |
EPS: | $-0.00150 |
FY | 2023 |
Pajamos: | $-227 300 |
Bruto pelnas: | $-737 100 (324.29 %) |
EPS: | $-8.51 |
FY | 2022 |
Pajamos: | $1.11M |
Bruto pelnas: | $293 700 (26.49 %) |
EPS: | $-7.24 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
VistaGen Therapeutics Inc
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.